Peptide and composition containing the same for anti-inflammation, anti-fibrosis, wound healing, and anticancer treatment

Patent metadata

Field	Value
Publication number	US-10676507-B2
Application number	US-201615576111-A
Country	US
Kind code	B2
Filing date	May 25, 2016
Priority date	May 26, 2015
Publication date	Jun 9, 2020
Grant date	Jun 9, 2020

Abstract

Peptides and compositions comprising the peptides, and more particularly, a peptide effective in anti-inflammation, anti-fibrosis, wound healing, and anti-cancer treatment, and a composition including the same are described. The peptides provided herein and the compositions comprising the peptides exhibit an effect of alleviating, preventing, or treating inflammation, fibrosis, wounds, and symptoms of diseases such as cancer including these symptoms, and thus may provide a method of preventing or treating associated diseases.

First claim

The invention claimed is:

1. A peptide having an amino acid sequence of SEQ ID NO:12 or consisting of an amino acid sequence of SEQ ID NO:10.

2. A pharmaceutical composition comprising the peptide or a pharmaceutically acceptable salt thereof according to claim 1 .

3. The pharmaceutical composition of claim 2 , wherein the composition has an anti-inflammatory activity due to a decrease in TNF-α.

4. The pharmaceutical composition of claim 3 , wherein the composition prevents or treats any one or more inflammation-associated diseases selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematosus (SLE), chronic obstructive pulmonary disease (COPD), septicemia, endotoxin shock, hepatitis, and type 1 diabetes.

5. The pharmaceutical composition of claim 2 , wherein the composition alleviates fibrosis of a body organ.

6. The pharmaceutical composition of claim 5 , wherein the composition has an activity of inhibiting fibrosis of a body organ by TGF-β signaling inhibition.

7. The pharmaceutical composition of claim 5 , wherein the composition prevents or treats fibrosis induced by one or more selected from the group consisting of cancer, administration of an anticancer drug, and radiation exposure.

8. The pharmaceutical composition of claim 7 , wherein the cancer is selected from the group consisting of pancreatic cancer, colon cancer, stomach cancer, prostate cancer, non-small cell lung cancer, breast cancer, melanoma, and ovarian cancer.

9. The pharmaceutical composition of claim 2 , wherein the composition treats or alleviates a wound.

10. The pharmaceutical composition of claim 9 , wherein the composition has a wound healing effect by inducing collagen synthesis.

11. The pharmaceutical composition of claim 9 , wherein the wound is selected from the group consisting of epidermal burns, epidermal lacerations, epidermal wounds, and combinations thereof.

12. The pharmaceutical composition of claim 2 , wherein the composition improves a skin condition.

13. The pharmaceutical composition of claim 12 , wherein the skin condition is selected from the group consisting of skin wrinkles according to skin aging, skin dryness, scars, reduced skin elasticity, and skin dents.

14. The pharmaceutical composition of claim 2 , wherein the composition is an anti-cancer composition.

15. A pharmaceutical kit comprising:
the pharmaceutical composition according to claim 2 ; and
an instruction instructing one or more selected from a dose, administration route, the number of doses, and indications of the composition.

16. A cosmetic composition comprising the peptide or a salt thereof according to claim 1 .

Assignees

• Gemvax & Kael Co Ltd
• Kim Sang Jae

Inventors

• Kim Sang Jae

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title